You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
綠葉製藥(02186.HK)力撲素獲CSCO乳腺癌診療指南一線化療推薦
格隆匯 04-22 22:33

格隆匯4月22日丨綠葉製藥(02186.HK)發佈公告,集團的創新紫杉醇脂質體制劑—力撲素獲得中國臨牀腫瘤學會(CSCO)乳腺癌診療指南推薦,用於Her2陰性晚期乳腺癌一線解救化療。

根據指南:在Her2陰性復發轉移乳腺癌的治療中,對於既往蒽環類治療失敗或蒽環類和紫杉類治療失敗的患者,推薦紫杉醇脂質體用於一線解救化療。

力撲素為集團的專利製備紫杉醇類製劑,運用創新的脂質體給藥劑,用於非小細胞肺癌、卵巢癌、乳腺癌等若干類癌症的化學治療。集團在中國持有紫杉醇脂質體的組成和配方專利。於本公告日期,力撲素為全球首個及唯一獲批准銷售的紫杉醇脂質體產品。根據IQVIA的資料,力撲素為2019年中國最普遍採用的抗癌藥品之一。

紫杉醇脂質體已作為一線藥物被寫入《CSCO原發性肺癌診療指南(2019版)》、並被納入《婦科惡性腫瘤紫杉類藥物臨牀應用專家共識》、《乳腺癌中紫杉類藥物臨牀應用專家共識(2020年)》中。此外,紫杉醇脂質體還作為多項放化療首選聯合用藥入選《中國食管癌放射治療指南(2019版)》。

董事會相信,力撲素獲得指南推薦代表該產品在臨牀應用上獲得高度認可,並將顯着提升產品在相關適應症上的滲透率,為力撲素的長期增長注入動力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account